Loading
A phase 3 trial of Limertinib run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active.
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT04143607 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 337 participants enrolled, started 2019-07-23. Conditions listed: Locally Advanced or Metastatic NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Limertinib, Aosaikang Pharmaceutical, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/